Pancreatic Cancer Research

ResearcherZhongnan Hospital of Wuhan UniversityActive in the last 2 years

Zhiyong Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6402-4034; OpenAlex author ID A5101590655. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 3 papers

Papers 8

  1. Improved Predictability of Diagnosis and Prognosis Using Serum- and Tissue-Derived Extracellular Vesicles From Bulk mRNA Sequencing in Pancreatic Ductal Adenoc… Co-author DOI 10.1002/cam4.70538↗
  2. Prognostic and immune microenvironment analysis of cuproptosis-related lncRNAs in human pancreatic cancer. Co-author DOI 10.1016/j.compbiomed.2025.111004↗
  3. METTL3/IGF2BP3 mediates ORC6 via N6-methyladenosine modification to promote the progression of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gene.2025.149468↗
  4. Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival. Last author DOI 10.1007/s12672-022-00495-0↗
  5. Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk. Co-author DOI 10.1158/0008-5472.can-21-4367↗
  6. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Co-author DOI 10.1007/s13402-019-00476-6↗
  7. Pancreatic cancer cell-derived exosomal microRNA-27a promotes angiogenesis of human microvascular endothelial cells in pancreatic cancer via BTG2. Last author DOI 10.1111/jcmm.14766↗
  8. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Co-author DOI 10.1159/000334103↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenjing Song · 2 shared papers, 2022–2025 · strength 0.39
  2. Yufeng Yuan · 2 shared papers, 2020–2025 · strength 0.38
  3. Ming Tian · 1 shared paper, 2025 · strength 0.26
  4. Qian Zhu · 1 shared paper, 2025 · strength 0.26
  5. Hong Duo · 1 shared paper, 2025 · strength 0.25
  6. Qifa Ye · 1 shared paper, 2025 · strength 0.25
  7. Zhiliang Wang · 1 shared paper, 2025 · strength 0.25
  8. Zhi‐Nan Chen · 1 shared paper, 2025 · strength 0.23
  9. Yang Shi · 1 shared paper, 2025 · strength 0.23
  10. Heshui Wu · 2 shared papers, 2011–2020 · strength 0.16
  11. Tao Peng · 1 shared paper, 2020 · strength 0.13
  12. Dan Shang · 1 shared paper, 2020 · strength 0.13
  13. Jianbo Tian · 1 shared paper, 2022 · strength 0.11
  14. Ying Zhu · 1 shared paper, 2022 · strength 0.11
  15. Min Wang · 1 shared paper, 2022 · strength 0.11
  16. Xiaoping Miao · 1 shared paper, 2022 · strength 0.11
  17. Pingting Ying · 1 shared paper, 2022 · strength 0.11
  18. Ming Zhang · 1 shared paper, 2022 · strength 0.11
  19. Jiang Chang · 1 shared paper, 2022 · strength 0.11
  20. Tao Yin · 1 shared paper, 2011 · strength 0.03
  21. Shanmiao Gou · 1 shared paper, 2011 · strength 0.03
  22. Chunyou Wang · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.